When examining in the training and validation sets separately, in the training set, IGHV SHMhigh was associated with better OS and PFS with and without the exclusion of patients with BCL2-R+ DLBCL; in the validation set, IGHV SHMhigh was associated with significantly better OS only after the exclusion of patients with BCL2-R+ DLBCL (Fig. 1b). The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.